Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
IRF5 genetic risk variants drive myeloid-specific IRF5 hyperactivation and presymptomatic SLE
Dan Li, … , Peter Linsley, Betsy J. Barnes
Dan Li, … , Peter Linsley, Betsy J. Barnes
Published December 26, 2019
Citation Information: JCI Insight. 2020;5(2):e124020. https://doi.org/10.1172/jci.insight.124020.
View: Text | PDF
Research Article Genetics Immunology

IRF5 genetic risk variants drive myeloid-specific IRF5 hyperactivation and presymptomatic SLE

  • Text
  • PDF
Abstract

Genetic variants within or near the interferon regulatory factor 5 (IRF5) locus associate with systemic lupus erythematosus (SLE) across ancestral groups. The major IRF5-SLE risk haplotype is common across populations, yet immune functions for the risk haplotype are undefined. We characterized the global immune phenotype of healthy donors homozygous for the major risk and nonrisk haplotypes and identified cell lineage–specific alterations that mimic presymptomatic SLE. Contrary to previous studies in B lymphoblastoid cell lines and SLE immune cells, IRF5 genetic variants had little effect on IRF5 protein levels in healthy donors. Instead, we detected basal IRF5 hyperactivation in the myeloid compartment of risk donors that drives the SLE immune phenotype. Risk donors were anti-nuclear antibody positive with anti-Ro and -MPO specificity, had increased circulating plasma cells and plasmacytoid dendritic cells, and had enhanced spontaneous NETosis. The IRF5-SLE immune phenotype was conserved over time and probed mechanistically by ex vivo coculture, indicating that risk neutrophils are drivers of the global immune phenotype. RNA-Seq of risk neutrophils revealed increased IRF5 transcript expression, IFN pathway enrichment, and decreased expression of ROS pathway genes. Altogether, the data support that individuals carrying the IRF5-SLE risk haplotype are more susceptible to environmental/stochastic influences that trigger chronic immune activation, predisposing to the development of clinical SLE.

Authors

Dan Li, Bharati Matta, Su Song, Victoria Nelson, Kirsten Diggins, Kim R. Simpfendorfer, Peter K. Gregersen, Peter Linsley, Betsy J. Barnes

×

Figure 4

IRF5 homozygous risk donors have elevated numbers of circulating pDCs and spontaneous NETosis.

Options: View larger image (or click on image) Download as PowerPoint

IRF5 homozygous risk donors have elevated numbers of circulating pDCs a...
(A and B) Similar to Figure 2, A and B, except freshly isolated PBMCs were surface-stained and pDCs gated as CD45+CD123+BDCA2+. (A) Representative dot plots from flow cytometry are shown from a single round of blood draws. A is pregated for CD45. (B) The number of circulating pDCs from n = 10 risk and n = 12 nonrisk donors is shown as a percentage of CD45+ gate (unpaired 2-tailed t test). (C) Representative dot plots from flow cytometry analysis of myeloperoxidase-positive, citrullinated histone H3–positive (MPO+cit-H3+) NETs in donor samples (n = 5 risk and nonrisk). C is pregated on CD66b+ cells. (D) Quantification of NETs from n = 12 risk and n = 14 nonrisk donors is shown as a percentage from CD66b+ cells (1-way ANOVA with Tukey’s multiple-comparisons test). (E) The presence of NETs was visualized by plating equal numbers of freshly isolated neutrophils from homozygous nonrisk, risk, and patients with SLE on poly-l-lysine–coated coverslips for 4 hours. Representative images are from staining with Sytox green and DAPI or MPO, Cit-H3, and DAPI. PMA was used as a positive control for NET induction on nonrisk neutrophils (original magnification ×20). Experiments were repeated 3 times (A–E). Single data points represent individual donors. Data are presented as mean ± SEM. *P ≤ 0.05.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts